Omvoh

OMVOH is indicated for the treatment of:

• moderately to severely active ulcerative colitis in adults.
• moderately to severely active Crohn's disease in adults.

• Evaluate patients for tuberculosis (TB) infection.
• Obtain liver enzymes and bilirubin levels.
• Complete all age-appropriate vaccinations according to current immunization guidelines.

• The 200 mg/2 mL prefilled pen and prefilled syringe are only for maintenance treatment of Crohn's disease.

• Induction Dosage
  : Week 0, Week 4, and Week 8: Infuse 300 mg intravenously over at least 30 minutes.
• Maintenance Dosage
  : Week 12 and every 4 weeks thereafter: Inject 200 mg subcutaneously (given as two consecutive injections of 100 mg each).

• Induction Dosage
  : Week 0, Week 4, and Week 8: Infuse 900 mg intravenously over at least 90 minutes.
• Maintenance Dosage
  : Week 12 and every 4 weeks thereafter: Inject 300 mg subcutaneously (given as two consecutive injections of 100 mg and 200 mg in any order).

• See the full prescribing information for preparation, administration and storage information for intravenous infusion and subcutaneous injection.

OMVOH is a clear to opalescent, colorless to slightly yellow to slightly brown solution available as:

• Intravenous Infusion:
  
  Injection: 300 mg/15 mL (20 mg/mL) solution in a single-dose vial
• Subcutaneous Use:
  
  Injection: 100 mg/mL solution in a single-dose prefilled pen
  
  Injection: 100 mg/mL solution in a single-dose prefilled syringe
  
  Injection: 200 mg/2 mL solution in a single-dose prefilled pen
  
  Injection: 200 mg/2 mL (100 mg/mL) solution in a single-dose prefilled syringe

There will be a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to OMVOH during pregnancy. Pregnant women exposed to OMVOH and healthcare providers are encouraged to call Eli Lilly and Company at 1-800-Lilly-Rx (1-800-545-5979).